Original-Research: Cardiol Therapeutics (von GBC AG): BUY boersennews.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from boersennews.de Daily Mail and Mail on Sunday newspapers.
Analyst: Julien Desrosiers; Felix Haugg
The Company announced topline results from its Phase I Single and Multiple
Ascending Dose Clinical Trial of CardiolRx(TM). CardiolRx is a
pharmaceutically produced oral cannabidiol formulation being developed for
the treatment of acute and chronic inflammation associated with heart
disease. These results positively support Cardiol Therapeutics proposed
treatment dosage for their upcoming CardiolRx Phase II and Phase II/III
trials. David Elsley, President and CEO of Cardiol Therapeutics, stated: Cardiol is initiating a Phase II/III clinical trial in the U.S.
investigating the cardioprotective properties of CardiolRx in 422
hospitalized patients with COVID-19 with a prior history of, or risk